Category «Phase 2»

Deutivacaftor

It’s only fair to share… Deutivacaftor RN: 1413431-07-8 UNII: SHA6U5FJZL,  N-[2-tert-butyl-4-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-5-hydroxyphenyl]-4-oxo-1H-quinoline-3-carboxamide Molecular Formula, C24-H28-N2-O3, Molecular Weight, 401.552 Synonyms CTP-656 D9-ivacaftor Deutivacaftor Ivacaftor D9 UNII-SHA6U5FJZL VX-561 WHO 10704 Treatment of Cystic Fibrosis Originator Concert Pharmaceuticals Class Amides; Aminophenols; Antifibrotics; Organic deuterium compounds; Quinolones; Small molecules Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants Orphan Drug Status Yes – Cystic fibrosis Phase II Cystic …

VX-659, Bamocaftor potassium

It’s only fair to share… VX-659, BAMOCAFTOR N-(Benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide 3-Pyridinecarboxamide, N-(phenylsulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]- N-(benzenesulfonyl)-6-[3-[2-[l-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-l-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide CAS Number 2204245-48-5 UNII: 8C7XEW3K7S BAMOCAFTOR M. Wt 591.65 Formula C28H32F3N5O4S     Bamocaftor potassium CAS 2204245-47-4 Molecular Formula C28 H31 F3 N5 O4 S . K  Molecular Weight 629.735 VX-659 VX-659 potassium salt VY7D8MTV72 (UNII code) WHO 11167 3-Pyridinecarboxamide, N-(phenylsulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]-, potassium salt (1:1) Potassium (benzenesulfonyl)[6-(3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carbonyl]azanide PHASE 2 CYSTIC …

Rovafovir Etalafenamide

It’s only fair to share… Rovafovir etalafenamide GS-9131 UNII-U8S0IC8DY7  ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate L-Alanine, N-((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydro-2-furanyl)oxy)methyl)phenoxyphosphinyl)-, ethyl ester CAS: 912809-27-9 Chemical Formula: C21H24FN6O6P Molecular Weight: 506.43 Originator Gilead Sciences Class Antiretrovirals; Purine nucleosides; Small molecules Mechanism of Action Nucleoside reverse transcriptase inhibitors Phase II HIV-1 infections 03 Apr 2018 Phase-II clinical trials in HIV-1 infections (Treatment-experienced) in Uganda (PO) (NCT03472326) 21 Mar 2018 Gilead …

OLACAFTOR, VX 440

It’s only fair to share… OLACAFTOR, VX 440 CAS 1897384-89-2 Molecular Formula: C29H34FN3O4S Molecular Weight: 539.666 g/mol CFTR corrector; UNII-RZ7027HK8F; RZ7027HK8F; Target-based Actions, CFTR modulator Indications, Cystic fibrosis CS-0044588 UNII-RZ7027HK8F RZ7027HK8F Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, shows the potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of …

Fezolinetant, фезолинетант , فيزولينيتانت , 非唑奈坦 ,

It’s only fair to share… Fezolinetant ESN-364 Molecular FormulaC16H15FN6OS Average mass358.393 Da Methanone, [(8R)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl](4-fluorophenyl)- UNII:83VNE45KXX фезолинетант [Russian] [INN] فيزولينيتانت [Arabic] [INN] 非唑奈坦 [Chinese] [INN] (4-Fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]methanone 10205 1629229-37-3 [RN] 83VNE45KXX Originator Euroscreen Developer Ogeda Class Pyrazines; Small molecules; Triazoles Mechanism of Action Gonadal steroid hormone modulators; Neurokinin 3 receptor antagonists Phase II Hot flashes; Polycystic ovary syndrome; Uterine leiomyoma Preclinical Weight gain DiscontinuedBenign prostatic hyperplasia; Endometriosis 14 Sep 2018 Ogeda completes …

Beclabuvir

It’s only fair to share… BMS-791325, Beclabuvir IN PHASE 2 for Hepatitis C (HCV) An NS5B inhibitor. BMS-791325 preferably is CAS 958002-33-0 958002-36-3 (as hydrochloride) C36 H45 N5 O5 S, 659.838 Cycloprop(d)indolo(2,1-a)(2)benzazepine-9-carboxamide, 12-cyclohexyl-N-((dimethylamino)sulfonyl)-4b,5,5a,6-tetrahydro-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-, (4bS,5aR)- (4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide (4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide (1aR,12bS)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide Cycloprop [d] indolo [2, 1 -a] [2]benzazepine-5-carboxamide, 8-cyclohexyl-N- [(dimethylamino)sulfonyl]-l,la,2,12b-tetrahydro-ll-methoxy-la-[(3-methyl-3,8- diazabicyclo[3.2.1]oct-8-yl)carbonyl]-, (laR,12bS)- Bristol-Myers Squibb (Originator) RNA-Directed RNA Polymerase (NS5B) …

Golvatinib, ゴルバチニブ

It’s only fair to share… Golvatinib E-7050, cas 928037-13-2 1-N’-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1,1-Cyclopropanedicarboxamide, N-[2-fluoro-4-[[2-[[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]amino]-4-pyridinyl]oxy]phenyl]-N’-(4-fluorophenyl)- [ACD/Index Name] 516Z3YP58E 928037-13-2 [RN] 9565 E7050, ゴルバチニブ Molecular Formula: C33H37F2N7O4 Molecular Weight: 633.701 g/mol N’-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide UNII:516Z3YP58E Originator Eisai Co Ltd Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Piperazines; Piperidines; Pyridines; Small molecules Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists Discontinued Gastric cancer; …

Epitinib

It’s only fair to share… Epitinib succinate; HMPL-813; Huposuan yipitini 1203902-67-3, 430.50, C24 H26 N6 O2 1-Piperazinecarboxamide, 4-ethyl-N-[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]- 4-Ethyl-N-[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]-1-piperazinecarboxamide Cancer; Glioblastoma; Non-small-cell lung cancer Epitinib is in phase I clinical trials by Hutchison MediPharma for the treatment of solid tumours. Epitinib succinate is an oral EGFR tyrosine kinase inhibitor in early clinical development at Hutchison China MediTech (Chi-Med) for the …

VIXOTRIGINE, раксатригин , راكساتريجين , 维索曲静 ,

It’s only fair to share… VIXOTRIGINE Molecular FormulaC18H19FN2O2 Average mass314.354 Da раксатригин , راكساتريجين , 维索曲静 , (5R)-5-{4-[(2-Fluorobenzyl)oxy]phényl}-L-prolinamide 10287 2-Pyrrolidinecarboxamide, 5-[4-[(2-fluorophenyl)methoxy]phenyl]-, (2S,5R)- 934240-30-9 [RN] QQS4J85K6Y Raxatrigine UNII:QQS4J85K6Y Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[4]Following this, vixotrigine …

BMS 986142

It’s only fair to share… BMS-986142 (2S,5R,3S)-6-fluoro-5-(3-(8-fluoro-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-2-methylphenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-l-methyl-2,4-dioxo-l,2-dihydroquinazolin-3(4H)-yl)-2- methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-lH-carbazole-8- carboxamide Molecular Formula, C32-H30-F2-N4-O4, Molecular Weight, 572.609, RN: 1643368-58-4 UNII: PJX9GH268R Originator Bristol-Myers Squibb Class Anti-inflammatories; Antirheumatics; Small molecules Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors Phase II Rheumatoid arthritis; Sjogren’s syndrome 24 Jun 2018 Biomarkers information updated 07 Jun 2018 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Argentina, Austria, Belgium, …